Contribution of interleukin 27 serum level to pathogenesis and prognosis in children with immune thrombocytopenia. Issue 25 (24th June 2022)

• Record Type: Journal Article
• Authors: Hassan, Tamer; Abdel Rahman, Doaa; Raafat, Nermin; Fathy, Manar; Shehab, Mohamed; Hosny, Ahmed; Fawzy, Reham; Zakaria, Marwa
• Is Part Of: Medicine. Volume 101:Issue 25(2022)
• Page Start: e29504
• Publication Date: 2022-06-24
• Subjects: IL-27 -- ITP -- pathogenesis -- platelets; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000029504
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Concepts surrounding the mechanisms of thrombocytopenia in ITP have shifted from the traditional view of autoantibody mediated platelet destruction to more complex mechanisms in which impaired platelet production, T-cell-mediated effects, and disturbed cytokine profiles play a role. Interleukin 27 (IL-27) plays pleiotropic roles in immunomodulation and autoimmune diseases. We aimed to determine the level of IL-27 in patients with ITP and its relationship to patient and disease characteristics as well as disease chronicity and response to treatment. Sixty childrens with primary immune thrombocytopenia were consequetively enrolled in this study as well as 20 age and sex matched healthy controls. ITP patients had significantly higher levels of IL-27 than controls (770.6 and 373.8 pg/ml, respectively). Patients with acute ITP had the highest levels of IL-27 among patient groups, while patients in remission had the lowest IL-27 levels (860.1and 622.9 pg/ml, respectively). Patients who received IVIG and combined steroids plus IVIG had significantly higher IL-27 levels than others. Patients who received Eltrombopag had significantly lower IL-27 levels than others. IL-27 seems to play a role in pathogenesis of childhood ITP. IL-27 can be used as a predictor for disease occurrence as well as responsiveness to treatment.